Press Release
Research Confirms New Nasal Decongestant Product Is Highly Meth-Resistant Yet Offers Same Effectiveness as Leading Pseudoephedrine Brand
"NEXAFED®, with its unique IMPEDE® technology, was specifically developed to address two key issues: to treat nasal congestion and to fight illicit meth production," said
The study measured the ability of NEXAFED's IMPEDE technology to disrupt the extraction and conversion of PSE by meth cooks using common clandestine meth lab processes. When simulating large scale manufacturing to extract and convert pure PSE into meth, researchers found that NEXAFED's IMPEDE technology yielded no measurable PSE extraction, representing a significant impediment compared to the control Sudafed® tablets (Sudafed® is a registered trademark and product of Johnson & Johnson). When tested under the "one-pot" conversion method, the study indicated that current IMPEDE technology tablets had an approximate 38 percent yield, nearly half the average meth recovered compared to the control. Currently,
To test the therapeutic equivalence of NEXAFED,
"The advent of new pseudoephedrine products with deterrent technologies, such as NEXAFED®, provides a significant value to cold and allergy sufferers, pharmacists and law enforcement officials in the fight against meth abuse," said
For more information about NEXAFED, which is currently distributed through national and regional drug wholesalers to chain and independent drugstores nationwide, and for updates on the rollout of the new IMPEDE 2.0 technology, visit JOIN-FIGHT.COM.
About NEXAFED®
NEXAFED® [pseudoephedrine hydrochloride] is a 30 mg immediate-release abuse-deterrent decongestant. The next generation pseudoephedrine tablet combines effective nasal congestion relief with IMPEDE technology, a unique polymer matrix that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine. IMPEDE technology forms a thick gel when the tablets are dissolved in solvents typically used in the pseudoephedrine extraction or methamphetamine production processes, trapping the pseudoephedrine or converted methamphetamine to resist its isolation or purification.
About
Forward Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to, the timing of our ability to successfully develop and launch our next generation NEXAFED Tablets, the market acceptance of and competitive environment for any of our products, the willingness of wholesalers and pharmacies to stock NEXAFED Tablets, expectations regarding potential market share for our products and the timing of first sales, the adequacy of the
results of the laboratory and clinical studies completed to date, the sufficiency of our development to meet over-the-counter, or OTC, Monograph standards as applicable, adverse safety findings relating to our product candidates, our exposure to product liability and other lawsuits in connection with the commercialization of our products, the increasing cost of insurance and the availability of product liability insurance coverage, and whether our IMPEDE technology, including our NEXAFED Tablets, will disrupt the processing of pseudoephedrine into methamphetamine, including whether NEXAFED will prove resistant to methamphetamine conversion methods that may be utilized in the future by clandestine methamphetamine laboratories. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates,"
"believes," indicated," "estimates," "projects," "predicts," "potential" and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the
Contacts
Investor Relations:
Email Contact
847-705-7709
Media Relations:
Spectrum
Email Contact
202-955-6222
Source:
News Provided by Acquire Media